The therapy is being tested for those with severe hypertriglyceridemia (sHTG), mixed dyslipidemia, and familial hypercholesterolemia (HoFH/HeFH). 🚀 Future Outlook
Targeted protein levels decreased by an average of 73%. ATHENA HEART 310
The treatment has been generally well-tolerated, with minor side effects like back pain or nausea reported during infusion. 🧬 Mechanism and Targets The therapy is being tested for those with
Recent data from clinical studies, including updates as of late 2025, show significant efficacy in participants: including updates as of late 2025
ANGPTL3 is a protein that normally inhibits enzymes that clear lipids from the blood. By "turning off" this gene, the body can more effectively remove fats.
Average drops of ~55% at the highest dose, with some patients seeing up to 84% reduction .